Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.

Abstract

We studied the time course for the reversal of rifampin's effect on the pharmacokinetics of oral midazolam (a cytochrome P450 (CYP) 3A4 substrate) and digoxin (a P-glycoprotein (P-gp) substrate). Rifampin increased midazolam metabolism, greatly reducing the area under the concentration-time curve (AUC(0-∞)). The midazolam AUC(0-∞) returned to baseline with a half-life of ~8 days. Rifampin's effect on the AUC(0-3 h) of digoxin was biphasic: the AUC(0-3 h) increased with concomitant dosing of the two drugs but decreased when digoxin was administered after rifampin. Digoxin was found to be a weak substrate of organic anion-transporting polypeptide (OATP) 1B3 in transfected cells. Although the drug was transported into isolated hepatocytes, it is not likely that this transport was through OATP1B3 because the transport was not inhibited by rifampin. However, rifampin did inhibit the P-gp-mediated transport of digoxin with a half-maximal inhibitory concentration (IC(50)) below anticipated gut lumen concentrations, suggesting that rifampin inhibits digoxin efflux from the enterocyte to the intestinal lumen. Pharmacokinetic modeling suggested that the effects on digoxin are consistent with a combination of inhibitory and inductive effects on gut P-gp. These results suggest modifications to drug-drug interaction (DDI) trial designs.

DOI: 10.1038/clpt.2010.271
02004002011201220132014201520162017
Citations per Year

631 Citations

Semantic Scholar estimates that this publication has 631 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Reitman2011RifampinsAI, title={Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.}, author={Marc L Reitman and Xiao-yan Chu and X. Cai and Jocelyn A Yabut and Raja Venkatasubramanian and Stefan C Zajic and Julie Stone and Yang Ding and Rose Witter and Charles E. Gibson and Kathryn Ann Roupe and Raymond Evers and John A. Wagner and Aubrey S Stoch}, journal={Clinical pharmacology and therapeutics}, year={2011}, volume={89 2}, pages={234-42} }